

LIGAND PHARMACEUTICALS INC
Form SC 13G
February 10, 2006

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)**

LIGAND PHARMACEUTICALS INCORPORATED

(NAME OF ISSUER)

COMMON STOCK

(Title of Class of Securities)

53220K207

(CUSIP Number)

DECEMBER 30,2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1 (b)

Rule 13d-1 (c)

Rule 13d-1 (d)

CUSIP No.
53220K207

13G

Page 1 of 3 pages

1. Names of reporting persons JPMorgan Chase & Co.

13-2624428

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY)

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

<i>NUMBER OF</i>	5.	SOLE VOTING POWER	5,455,900
<i>SHARES</i>			
<i>BENEFICIALLY</i>	6.	SHARED VOTING POWER	0
<i>OWNED BY</i>			
<i>EACH</i>	7.	SOLE DISPOSITIVE POWER	5,455,900
<i>REPORTING</i>			
<i>PERSON WITH</i>	8.	SHARED DISPOSITIVE POWER	0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,455,900

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.3%

12. TYPE OF REPORTING PERSON* HC

Item **Name of Issuer:**
1(a).

LIGAND PHARMACEUTICALS INCORPORATED

Item **Address of Issuer's Principal**
1(b). **Executive Offices:**

10275 SCIENCE CENTER DRIVE

SAN DIEGO, CA 92121-1117

Item **Name of Person Filing:**
2(a).

JPMorgan Chase & Co.

Item **Address of Principal Business Office**
2(b). **or, if None, Residence:**

270 PARK AVE

NEW YORK, NY 10017

Item **Citizenship**
2(c).

Delaware

Item **Title of Class of Securities:**
2(d).

COMMON STOCK

Unless otherwise noted, security being reported
is common stock

Item **CUSIP** **53220K207**
2(e). **Number:**

Item 3 **If this Statement is Filed Pursuant**
to Rule 13d-1(b), or 13d-2(b)

Or (c), Check Whether the Person
Filing is a :

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

- (a) Broker or dealer registered under Section 15 of the Exchange Act;
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act;
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (d) Investment company registered under Section 8 of the Investment Company Act;
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an Investment company under Section 3(c)(14) of the Investment Company act;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(b), check this box.

Item 4. Ownership

Provide the following information regarding the aggregate number and

Percentage of the class of securities of issuer identified in Item 1.

(a) Amount beneficially owned: 5,455,900

Including 0 shares where there is a Right to Acquire.

(b) Percent of class: 7.3%

(c) Number of shares as to which such person has:

(i)	Sole power to vote or to direct the vote:	5,455,900
(ii)	Shared power to vote or to direct the vote:	0
(iii)	Sole power to dispose or to direct the disposition of:	5,455,900
(iv)	Shared power to dispose or to direct the disposition of:	0

Item 5. Ownership of Five Percent or Less of a Class. NOT APPLICABLE

If this statement is being filed to report the fact that as of the date

hereof the reporting person has ceased to be the beneficial

owner of more

than five percent of the class of securities, check the following. ()

Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A

JPMorgan Chase & Co. is the beneficial owner of N/A shares of the

issuer's common stock on behalf of other persons known to have one or more of

the following:

the right to receive dividends for such securities;

the power to direct the receipt of dividends from such securities;

the right to receive the proceeds from the sale of such securities;

the right to direct the receipt of proceeds from the sale of such securities;

No such person is known to have an interest in more than 5% of the class of

securities reported herein unless such person is identified below.

Item 7. Identification and Classification of the Subsidiary Which Acquired the

**Security being reported on by the
Parent Holding Company.**

This notice is filed on behalf of JPMorgan
Chase & Co. and its wholly owned

Subsidiary (ies),

J.P. Morgan Ventures Corporation

**Item 8. Identification and Classification of
Members of the Group.**

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

**Item Certifications
10.**

By signing below I certify that, to the best of my knowledge
and belief,

the securities referred to above were not acquired and are
not held for the

purpose of or with the effect of changing or influencing the
control of the

issuer of the securities and were not acquired and are not held in connection

with or as a participant in any transaction having that purpose or effect.

Page 3 of 3 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the

information set forth in this statement is true, complete and correct.

Dated: FEBRUARY
10, 2006

JPMorgan Chase & Co.

By: /s/ Margaret R. Rubin

Margaret R. Rubin

Corporate Compliance

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

The original statement shall be signed by each person on whose behalf the statement

is filed or his authorized representative. If the statement is signed on behalf of

a person by his authorized representative (other than an executive officer or general

partner of the filing person), evidence of the representative's authority to sign on

behalf of such person shall be filed with the statement, provided, however, that a

power of attorney for this purpose which is already on file with the commission may

be incorporated by reference. The name and any title of each person who signs the

the statement shall be typed or printed beneath his signature.